Pneumonitis Risk in NSCLC Remains Uncertain, Obesity May Be Predictor

Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.

Related Keywords

United States , ,Thoracic Disease ,Computing Infrastructure ,Nsclc ,Obesity ,Durvalumab ,